A comparative study of two hormone replacement therapy regimens on safety and efficacy variables.
OBJECTIVE
To assess the effect of tibolone on endometrial safety, plasma estradiol concentrations, lipid metabolism and climacteric symptoms in comparison to sequential conjugated equine estrogens and medroxyprogesterone acetate in postmenopausal women.


METHODS
In a randomised, open-label, 6-cycle, group-comparative study, the effects on the aforementioned parameters were studied with tibolone 2.5 mg/day (N = 13) continuously, and with conjugated equine estrogens 0.625 mg/day continuously, combined with medroxyprogesterone acetate 5 mg/day (N = 11) (CEE/MPA) sequentially, during 12 days of each 28-day cycle. Within-group statistical analysis was performed with Student's t-test for paired samples, whereas between-group statistics were performed using the Student's t-test for independent groups.


RESULTS
Cytological evaluation revealed no endometrial stimulation in either group. In the tibolone group, there were no effects on estradiol levels, whereas in the CEE/MPA group, an increase in total and non-SHBG-bound estradiol plasma levels was reported. In the tibolone group, there were significant decreases in plasma total cholesterol, triglycerides, HDL-cholesterol and VLDL-cholesterol, whereas no significant changes in LDL-cholesterol and IDL-cholesterol were reported. In the CEE/MPA group there were significant decreases in plasma total cholesterol, HDL-cholesterol and LDL-cholesterol, whereas there were no significant changes in triglycerides, IDL-cholesterol and VLDL-cholesterol. Climacteric symptoms, particularly vasomotor episodes, decreased similarly in both groups.


CONCLUSIONS
Both tibolone and CEE/MPA were safe with respect to effects on the endometrium and both treatments induced changes in the plasma profiles of certain lipid and lipoprotein parameters. However, the overall clinical implications of these changes are unknown. Finally, both regimens were equally effective in the treatment of climacteric symptoms.
Siseles
N O
NO
Climacteric Section, Hospital Italiano, Buenos Aires, Argentina.
Halperin
H
H
Benencia
H J
HJ
Berg
G
G
Pilnik
S
S
Mesch
V
V
Arrighi
B
B
Wikinski
R W
RW
D045930:Anabolic Agents / Q000008:administration & dosage / Q000009:adverse effects; D002584:Cervix Uteri / Q000166:cytology / Q000187:drug effects; D004717:Endometrium / Q000166:cytology / Q000187:drug effects; D004958:Estradiol / Q000097:blood; D015914:Estrogen Replacement Therapy / Q000009:adverse effects; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D009652:Norpregnenes / Q000008:administration & dosage* / Q000009:adverse effects; D017698:Postmenopause / Q000097:blood; D014621:Vagina / Q000166:cytology / Q000187:drug effects
D045930:Anabolic Agents; D004966:Estrogens, Conjugated (USP); D008055:Lipids; D008074:Lipoproteins; D009652:Norpregnenes; D004958:Estradiol; D017258:Medroxyprogesterone Acetate; C027385:tibolone